Cargando…
Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
Autores principales: | Visconte, Valeria, Nawrocki, Steffan T., Espitia, Claudia M., Kelly, Kevin R., Possemato, Anthony, Beausoleil, Sean A., Han, Yingchun, Carraway, Hetty E., Nazha, Aziz, Advani, Anjali S., Maciejewski, Jaroslaw P., Sekeres, Mikkael A., Carew, Jennifer S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792796/ https://www.ncbi.nlm.nih.gov/pubmed/26369982 http://dx.doi.org/10.1038/leu.2015.250 |
Ejemplares similares
-
Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms
por: Visconte, Valeria, et al.
Publicado: (2016) -
Broad and potent antiviral activity of the NAE inhibitor MLN4924
por: Le-Trilling, Vu Thuy Khanh, et al.
Publicado: (2016) -
The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016) -
The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance
por: Du, Meng-ge, et al.
Publicado: (2021) -
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)